Mitra Keluarga 1H 2025 presentation: Revenue up 4.5% despite patient volume decline

PT Mitra Keluarga Karyasehat Tbk (MIKA) reported robust financial performance for 1H 2025, with revenue increasing 4.5% to IDR 2,563.46 billion and net income rising 6.0% to IDR 683.63 billion. This growth was achieved despite a 6.8% decline in overall patient volume, attributed to a successful strategic shift towards higher-value private patients, which now constitute 87.8% of revenue, driving strong profitability with a 37.7% EBITDA margin. MIKA maintains a strong balance sheet with over IDR 2.4 billion in cash and zero debt, supporting aggressive expansion plans including 7 new hospitals and IDR 1 trillion in 2025 capital expenditure, positioning the company for continued growth in Indonesia's private healthcare sector.

Analysis

PT Mitra Keluarga Karyasehat Tbk (MIKA) demonstrated strong financial performance in H1 2025, with revenue growing 4.5% year-over-year to IDR 2,563.46 billion and net income increasing 6.0% to IDR 683.63 billion. This growth is particularly noteworthy as it occurred despite a 6.8% decline in overall patient volume, highlighting a successful strategic pivot towards higher-value services. The company's revenue from private patients increased by 6.8%, now accounting for 87.8% of total revenue, which successfully offset a 15.1% decrease in lower-margin government-insured (JKN) revenue. This shift has sustained robust profitability, evidenced by an EBITDA margin of 37.7% and a Return on Invested Capital (ROIC) of 39.5%. The company's financial position is exceptionally strong, characterized by a zero-debt balance sheet and a cash position exceeding IDR 2.46 billion. Operationally, MIKA has significantly improved its efficiency, reducing its cash cycle from 13 days to -7 days. This financial strength underpins an aggressive expansion strategy, with a budgeted IDR 1,000 billion in capital expenditure for 2025 to add approximately 1,400 new beds across seven hospital sites, primarily in the high-growth regions of Greater Jakarta and Surabaya.

Key Decisions for Investors

• Investors should recognize the company's ability to grow both top and bottom lines despite falling patient volumes as evidence of strong pricing power and a successful strategic execution on shifting its payer mix to higher-margin private clients.
• The aggressive expansion plan, funded by a robust debt-free balance sheet, presents a clear catalyst for future growth; however, investors must monitor the execution, particularly the timeline and profitability ramp-up of the new hospitals, to ensure the IDR 1 trillion capex budget generates expected returns.
• While the strategic shift is currently effective, the persistent decline in patient admissions (down 9.7%) and outpatient visits (down 6.4%) is a key risk to watch, as it could eventually limit growth if the benefits from pricing and mix optimization diminish.
• Given the stock is trading considerably off its 52-week high, the current valuation may offer an attractive entry point for those confident in management's proven ability to execute its expansion strategy and maintain high profitability.